loading page

Type-2 inflammatory mediators as targets for precision medicine in children
  • +2
  • Amelia Licari,
  • Riccardo Castagnoli,
  • Sara Manti,
  • Elena Chiappini,
  • Gian Luigi Marseglia
Amelia Licari
Fondazione IRCCS Policlinico San Matteo
Author Profile
Riccardo Castagnoli
Universita degli Studi di Pavia
Author Profile
Sara Manti
UOC Genetics and Immunology Paediatrics
Author Profile
Elena Chiappini
University of Florence, Meyer Children's Hospital
Author Profile
Gian Luigi Marseglia
Fondazione IRCCS Policlinico San Matteo
Author Profile

Abstract

The prevalence, heterogeneity and severity of type 2 inflammatory diseases, including asthma and atopic dermatitis, continue to rise, especially in children and adolescents. Type 2 inflammation is mediated by both the innate and adaptive immune cells and sustained by a specific subset of cytokines, such as interleukin(IL)‐4, IL‐5,IL‐13, and IgE. IL-4 and IL-13 are considered signature type 2 cytokines, as they both have a pivotal role in many of the pathobiological changes featured in asthma and atopic dermatitis. Several biologics targeting IL-4, IL-5, and IL-13, as well as IgE, have been proposed to treat severe allergic disease in the pediatric population with promising results. A better definition of type 2 inflammatory pathways is essential to implement targeted therapeutic strategies.

Peer review status:ACCEPTED

06 Jul 2020Submitted to Pediatric Allergy and Immunology
06 Jul 2020Editorial Decision: Accept